Visfatin -948 G/T and resistin -420 C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseases

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorMotawi T.M.K.
dc.contributor.authorShaker O.G.
dc.contributor.authorEl-Sawalhi M.M.
dc.contributor.authorAbdel-Nasser Z.M.
dc.contributor.otherBiochemistry Department
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherCairo University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Medical Biochemistry and Molecular Biology Department
dc.contributor.otherFaculty of Medicine
dc.contributor.otherCairo University
dc.contributor.otherCairo
dc.contributor.otherEgypt; Biochemistry Department
dc.contributor.otherFaculty of Pharmacy
dc.contributor.otherModern Sciences and Arts University
dc.contributor.otherCairo
dc.contributor.otherEgypt
dc.date.accessioned2020-01-09T20:42:17Z
dc.date.available2020-01-09T20:42:17Z
dc.date.issued2014
dc.descriptionScopus
dc.description.abstractDiabetes mellitus is one of the main threats to human health in the 21st century. Visfatin/Nampt and resistin are novel adipokines that have been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) complication. Several genetic studies have shown inconsistent results regarding association of visfatin/Nampt gene (NAMPT) and resistin gene (RETN) polymorphisms with T2DM and CVD complications. Here, we investigate whether NAMPT -948G/T and RETN -420C/G polymorphisms are associated with T2DM, its CVD complications, and serum adipokines levels in 90 Egyptian diabetic patients (44 without CVD and 46 with CVD) along with 60 healthy control subjects. Higher frequencies of NAMPT -948G/G and RETN -420G/G were observed among T2DM patients compared with controls. Furthermore, the frequencies of these genotypes were significantly higher in T2DM patients with CVD than those without CVD. Both NAMPT -948G/G and RETN -420G/G genotypes and G alleles were significantly associated with T2DM and CVD in Egyptian diabetic patients. Moreover, serum visfatin/Nampt and resistin levels were markedly elevated in T2DM patients, with the highest values observed in G/G genotypes among T2DM patients with CVD. In addition, positive correlations were observed between plasma adipokines levels and CVD risk factors. In conclusion, our data suggests that genetic variations in NAMPT -948G/T and RETN -420C/G may contribute to the disposition for T2DM and its CVD complications in Egyptian patients. However, further studies with greater sample size should be performed to verify these results. 2014 Published by NRC Research Press.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=22211&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1139/gen-2014-0022
dc.identifier.doiPubMed ID 25120107
dc.identifier.issn8312796
dc.identifier.otherhttps://doi.org/10.1139/gen-2014-0022
dc.identifier.otherPubMed ID 25120107
dc.identifier.urihttps://t.ly/VZKqe
dc.language.isoEnglishen_US
dc.publisherNational Research Council of Canadaen_US
dc.relation.ispartofseriesGenome
dc.relation.ispartofseries57
dc.subjectOctober University for Modern Sciences and Arts
dc.subjectجامعة أكتوبر للعلوم الحديثة والآداب
dc.subjectUniversity of Modern Sciences and Arts
dc.subjectMSA University
dc.subjectCardiovascular diseaseen_US
dc.subjectNAMPT -948 G/Ten_US
dc.subjectPolymorphismsen_US
dc.subjectRETN -420 C/Gen_US
dc.subjectType 2 diabetes mellitusen_US
dc.subjectcytokineen_US
dc.subjectnicotinamide phosphoribosyltransferaseen_US
dc.subjectnicotinamide phosphoribosyltransferase, humanen_US
dc.subjectresistinen_US
dc.subjectRETN protein, humanen_US
dc.subjectadulten_US
dc.subjectblooden_US
dc.subjectcardiovascular diseaseen_US
dc.subjectCaucasianen_US
dc.subjectcomplicationen_US
dc.subjectdisease predispositionen_US
dc.subjectEgypten_US
dc.subjectfemaleen_US
dc.subjectgenetic associationen_US
dc.subjectgeneticsen_US
dc.subjecthumanen_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectnon insulin dependent diabetes mellitusen_US
dc.subjectsingle nucleotide polymorphismen_US
dc.subjectAdulten_US
dc.subjectCardiovascular Diseasesen_US
dc.subjectCytokinesen_US
dc.subjectDiabetes Mellitus, Type 2en_US
dc.subjectDisease Susceptibilityen_US
dc.subjectEgypten_US
dc.subjectEuropean Continental Ancestry Groupen_US
dc.subjectFemaleen_US
dc.subjectGenetic Association Studiesen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectNicotinamide Phosphoribosyltransferaseen_US
dc.subjectPolymorphism, Single Nucleotideen_US
dc.subjectResistinen_US
dc.titleVisfatin -948 G/T and resistin -420 C/G polymorphisms in Egyptian type 2 diabetic patients with and without cardiovascular diseasesen_US
dc.typeArticleen_US
dcterms.isReferencedByAntuna-Puente, B., Feve, B., Fellahi, S., Bastard, J.-P., Adipokines: The missing link between insulin resistance and obesity (2008) Diabetes Metab., 34 (1), pp. 2-11; Bailey, S.D., Loredo-Osti, J.C., Lepage, P., Faith, J., Fontaine, J., Desbiens, K.M., Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population (2006) Diabetes, 55 (10), pp. 2896-2902; Bastard, J.P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., Recent advances in the relationship between obesity, inflammation, and insulin resistance (2006) Eur. Cytokine Network, 17 (1), pp. 4-12. , 16613757; Bttcher, Y., Teupser, D., Enigk, B., Berndt, J., Klting, N., Schn, M.R., Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans (2006) J. Clin. Endocrinol. Metab., 91 (7), pp. 2725-2731; Chang, Y.-H., Chang, D.-M., Lin, K.-C., Shin, S.-J., Lee, Y.-J., Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A meta-analysis and systemic review (2011) Diabetes Metab. Res. Rev., 27 (6), pp. 515-527; Conneely, K.N., Silander, K., Scott, L.J., Mohlke, K.L., Lazaridis, K.N., Valle, T.T., Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects (2004) Diabetologia, 47 (10), pp. 1782-1788; El-Mesallamy, H.O., Kassem, D.H., El-Demerdash, E., Amin, A.I., Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus (2011) Metabolism, 60 (1), pp. 63-70; El-Shal, A.S., Pasha, H.F., Rashad, N.M., Association of resistin gene polymorphisms with insulin resistance in Egyptian obese patients (2013) Gene, 515 (1), pp. 233-238; Emamgholipour, S., Hossein-Nezhad, A., Najmafsha, R.A., Rahmani, M., Larijani, B., Promoter resistin gene polymorphism in patients with type 2 diabetes and its influence on concerned metabolic phenotypes (2009) Iran. J. Diabetes Lipid Disord., 2009, pp. 8-Dec. , 150-156; Fain, J.N., Cheema, P.S., Bahouth, S.W., Lloyd Hiler, M., Resistin release by human adipose tissue explants in primary culture (2003) Biochem. Biophys. Res. Commun., 300 (3), pp. 674-678; Filippatos, T.D., Randeva, H.S., Derdemezis, C.S., Elisaf, M.S., Mikhailidis, D.P., Visfatin/PBEF and atherosclerosis-related diseases (2010) Curr. Vasc. Pharmacol., 8 (1), pp. 12-28; Filippatos, T.D., Tsimihodimos, V., Derdemezis, C.S., Gazi, I.F., Saougos, V., Mikhailidis, D.P., Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile (2013) Nutr. Metab. Cardiovasc. Dis., 23 (4), pp. 330-336; Fujinami, A., Obayashi, H., Ohta, K., Ichimura, T., Nishimura, M., Matsui, H., Enzyme-linked immunosorbent assay for circulating human resistin: Resistin concentrations in normal subjects and patients with type 2 diabetes (2004) Clin. Chim. Acta, 339 (12), pp. 57-63; Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Visfatin: A protein secreted by visceral fat that mimics the effects of insulin (2005) Science, 307 (5708), pp. 426-430; Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Retraction (2007) Science, 318 (5850), p. 565. , 17962537; Gligor, R., Zdremtan, D., Pilat, L., Matei, I., Ionescu-T�rgovi?te, C., Cr�nic, I., Correlation of visfatin with the lipidic metabolism in diabetic and obese patients (2012) Proc. Rom. Acad., Series B, 1, pp. 37-43; Goldstein, B.J., Insulin resistance as the core defect in type 2 diabetes mellitus (2002) Am. J. Cardiol., 90 (5 A), pp. 3g-10g; Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B., Jr., Clark, L.T., Hunninghake, D.B., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines (2004) J. Am. Coll. Cardiol., 44 (3), pp. 720-732; Gulcelik, N.E., Usman, A., Grlek, A., Role of adipocytokines in predicting the development of diabetes and its late complications (2009) Endocrine, 36 (3), pp. 397-403; Hajer, G.R., Van Haeften, T.W., Visseren, F.L., Adipose tissue dysfunction in obesity, diabetes, and vascular diseases (2008) Eur. Heart J., 29 (24), pp. 2959-2971; Hivert, M.F., Sullivan, L.M., Fox, C.S., Nathan, D.M., D'Agostino, R.B., Sr., Wilson, P.W., Meigs, J.B., Associations of adiponectin, resistin, and tumor necrosis factor-? with insulin resistance (2008) J. Clin. Endocrinol. Metab., 93 (8), pp. 3165-3172; Hivert, M.F., Manning, A.K., McAteer, J.B., Dupuis, J., Fox, C.S., Cupples, L.A., Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study (2009) Diabetes, 58 (3), pp. 750-756; Hussain, S., Asghar, M., Javed, Q., Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients (2010) Transl. Res., 155 (3), pp. 142-147; Jamaluddin, M.S., Weakley, S.M., Yao, Q., Chen, C., Resistin: Functional roles and therapeutic considerations for cardiovascular disease (2012) Br. J. Pharmacol., 165 (3), pp. 622-632; Johansson, L.M., Johansson, L.E., Ridderstrle, M., The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects (2008) Metabolism, 57 (11), pp. 1558-1562; Krner, A., Bttcher, Y., Enigk, B., Kiess, W., Stumvoll, M., Kovacs, P., Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children (2007) Metabolism, 56 (6), pp. 772-777; Leander, K., Gigante, B., Silveira, A., Vikstrom, M., Hamsten, A., Hogberg, J., NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction (2012) Clin. Chim. Acta, 413 (78), pp. 727-732; Lim, S., Koo, B.K., Cho, S.W., Kihara, S., Funahashi, T., Cho, Y.M., Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS): A 42-month prospective study (2008) Atherosclerosis, 196 (1), pp. 398-404; Luk, T., Malam, Z., Marshall, J.C., Pre-B cell colony-enhancing factor (PBEF)/visfatin: A novel mediator of innate immunity (2008) J. Leukocyte Biol., 83 (4), pp. 804-816; Ma, X., Warram, J.H., Trischitta, V., Doria, A., Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians (2002) J. Clin. Endocrinol. Metab., 87 (9), pp. 4407-4410; Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: Insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man (1985) Diabetologia, 28 (7), pp. 412-419; McTernan, P.G., Kusminski, C.M., Kumar, S., Resistin (2006) Curr. Opin. Lipidol., 17 (2), pp. 170-175; Menzaghi, C., Coco, A., Salvemini, L., Thompson, R., De Cosmo, S., Doria, A., Trischitta, V., Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians (2006) J. Clin. Endocrinol. Metab., 91 (7), pp. 2792-2795; Menzaghi, C., Bacci, S., Salvemini, L., Mendonca, C., Palladino, G., Fontana, A., Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes (2013) PloS ONE, 8 (6), p. 64729; Miyamoto, Y., Morisaki, H., Kokubo, Y., Yamanaka, I., Tomoike, H., Okayama, A., Resistin gene variations are associated with the metabolic syndrome in Japanese men (2009) Obes. Res. Clin. Pract., 3, pp. 65-74; Norata, G.D., Ongari, M., Garlaschelli, K., Raselli, S., Grigore, L., Catapano, A.L., Plasma resistin levels correlate with determinants of the metabolic syndrome (2007) Eur. J. Endocrinol., 156 (2), pp. 279-284; Osawa, H., Tabara, Y., Kawamoto, R., Ohashi, J., Ochi, M., Onuma, H., Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population (2007) Diabetes Care, 30 (6), pp. 1501-1506; Paschou, P., Kukuvitis, A., Yavropoulou, M.P., Dritsoula, A., Giapoutzidis, V., Anastasiou, O., Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population (2010) Cytokine, 51 (1), pp. 25-27; Romacho, T., S�nchez-Ferrer, C.F., Peir�, C., Visfatin/Nampt: An adipokine with cardiovascular impact (2013) Mediators Inflammation, 2013, p. 946427; Saddi-Rosa, P., Oliveira, C.S., Giuffrida, F.M., Reis, A.F., Visfatin, glucose metabolism and vascular disease: A review of evidence (2010) Diabetol. Metab. Syndr., 2, p. 21; Saddi-Rosa, P., Viana De Oliveira, C.S., Crispim, F., Giuffrida, F.M., De Lima, V.C., Vieira, J.G., Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects (2013) Cardiovasc. Diabetol., 12 (1), p. 119; Scherer, P.E., Adipose tissue: From lipid storage compartment to endocrine organ (2006) Diabetes, 55 (6), pp. 1537-1545; Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030 (2010) Diabetes Res. Clin. Pract., 87 (1), pp. 4-14; Soumaya, K., Molecular mechanisms of insulin resistance in diabetes (2012) Adv. Exp. Med. Biol., 771, pp. 240-251; Suriyaprom, K., Phonrat, B., Namjuntra, P., Chanchay, S., Tungtrongchitr, R., The +299(G>A) resistin gene polymorphism and susceptibility to type 2 diabetes in Thais (2009) J. Clin. Biochem. Nutr., 44 (1), pp. 104-110; Tang, N.-P., Wang, L.-S., Yang, L., Zhou, B., Gu, H.-J., Sun, Q.-M., A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population (2008) Clin. Endocrinol., 68 (1), pp. 82-87; Tokuyama, Y., Osawa, H., Ishizuka, T., Onuma, H., Matsui, K., Egashira, T., Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus (2007) Metabolism, 56 (5), pp. 693-698; Tsukahara, T., Nakashima, E., Watarai, A., Hamada, Y., Naruse, K., Kamiya, H., Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients (2009) Diabetes Res. Clin. Pract., 84 (2), pp. 179-186; Ukkola, O., Kunnari, A., Kesaniemi, Y.A., Genetic variants at the resistin locus are associated with the plasma resistin concentration and cardiovascular risk factors (2008) Regul. Peptides, 149 (13), pp. 56-59; Uslu, S., Kebapci, N., Kara, M., Bal, C., Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus (2012) Exp. Ther. Med., 4 (1), pp. 113-120; Wen, Y., Lu, P., Dai, L., Association between resistin gene -420 C/G polymorphism and the risk of type 2 diabetes mellitus: A meta-analysis (2013) Acta Diabetol., 50 (2), pp. 267-272; Xie, H., Tang, S.-Y., Luo, X.-H., Huang, J., Cui, R.-R., Yuan, L.-Q., Insulin-like effects of visfatin on human osteoblasts (2007) Calcif. Tissue Int., 80 (3), pp. 201-210; Xu, J.Y., Sham, P.C., Xu, A., Tso, A.W., Wat, N.M., Cheng, K.Y., Resistin gene polymorphisms and progression of glycaemia in southern Chinese: A 5-year prospective study (2007) Clin. Endocrinol., 66 (2), pp. 211-217; Yan, J.-J., Tang, N.-P., Tang, J.-J., Jia, E.-Z., Wang, M.-W., Wang, Q.-M., Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population (2010) Clin. Chim. Acta, 411 (12), pp. 26-30; Zhang, L.Q., Heruth, D.P., Ye, S.Q., Nicotinamide phosphoribosyltransferase in human diseases (2011) J. Bioanal. Biomed., 3, pp. 13-25. , 22140607; Zhang, Y.-Y., Gottardo, L., Thompson, R., Powers, C., Nolan, D., Duffy, J., A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes (2006) Obesity, 14 (12), pp. 2119-2126
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper